BTTC Clinical Trial Results Get Presented at ASCO
Dr. Raizer was asked to present the results of the BTTC 08-01 clinical trial at the recent meeting of the American Society of Clinical Oncology. The trial was a phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. This is the first large trial exclusively completed by the BTTC. While the trial did not meet its therapeutic objective, the outcome results were comparable to other trials in MGMT unmethylated patients and might be a treatment option for patients who cannot tolerate temozolomide. Tumor tissue is being analyzed to determine if we can determine a group of patients who might benefit from this therapy.